The European Medicines Agency (EMA) has approved the use of Fexinidazole for the treatment of Human African Trypanosomiasis (HPA), also known as ‘sleeping sickness’. Fexinidazole is the first all-oral treatment for the sickness. It was developed in the 1980s by Hoechst, a German company and was rediscovered in 2005 by Drugs for Neglected Diseases Initiative (DNDi). Its approval for use could save thousands of lives in West and Central Africa where the sickness, caused by a parasite that is transmitted by the tsetse fly, not only causes severe disruption in sleep patterns but also aggression and, ultimately, death. Read more on GlobeNewswire.